Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Moinuddin Mokhashi

Pediatric Endocrinology Newhall, CA Medical Doctor

NPI 1821157298 CMS profile 264732

25078 Peachland Ave Ste A, Newhall, CA 91321

Open in the dashboard

General payments

$16,393

245 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Moinuddin Mokhashi of Newhall, CA is reported in the CMS Open Payments database as having received $16,393 across 245 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Pediatric Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $12,390 78
2024 General $1,241 60
2023 General $849 22
2022 General $681 32
2021 General $631 28
2020 General $289 11
2019 General $313 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Moinuddin Mokhashi
  • Pediatric Endocrinology median
  • Middle half of Pediatric Endocrinology
  • National median

In program year 2025, general payments to Moinuddin Mokhashi were reported at $12,390. Among 971 Pediatric Endocrinology profiles paid that year, the median was $293 and the middle half received between $106 and $1,640.

Show as a table
Year Moinuddin Mokhashi Pediatric Endocrinology median Middle half National median
2019 $313 $196 $68–$845 $163
2020 $289 $124 $37–$722 $114
2021 $631 $134 $35–$691 $132
2022 $681 $177 $47–$726 $149
2023 $849 $236 $75–$887 $160
2024 $1,241 $259 $91–$979 $164
2025 $12,390 $293 $106–$1,640 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sanofi-Aventis U.S. LLC $11,060 21 payments
  2. AbbVie, Inc. $1,133 58 payments
  3. Novo Nordisk Inc $865 24 payments
  4. Xeris Pharmaceuticals, Inc. $289 13 payments
  5. Rhythm Pharmaceuticals, Inc. $279 12 payments
  6. BioMarin Pharmaceutical Inc. $275 10 payments
  7. Pfizer Inc. $270 16 payments
  8. Ascendis Pharma, Inc. $262 12 payments
  9. Lilly USA, LLC $237 12 payments
  10. Kyowa Kirin, Inc. $194 3 payments
  11. Other $1,529 64 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $10,476 2 payments
  2. Food and Beverage $5,623 235 payments
  3. Education $294 8 payments
Products named General payments · program years 2019–2025
  1. TZIELD $11,060 21 payments
  2. LUPRON DEPOT $911 52 payments
  3. Sogroya $460 14 payments
  4. Imcivree $279 12 payments
  5. SKYTROFA $236 11 payments
  6. GENOTROPIN $225 14 payments
  7. NGENLA $222 14 payments
  8. BAQSIMI $219 11 payments
  9. CRYSVITA $194 3 payments
  10. GVOKE PFS $176 8 payments
  11. Other $2,517 105 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

245 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Endocrinology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record